Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day
Larimar Therapeutics (Nasdaq: LRMR) announced participation in the Guggenheim 4th Annual Immunology & Neurology Day on November 14-15, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Larimar Therapeutics (Nasdaq: LRMR) announced participation in the Guggenheim 4th Annual Immunology & Neurology Day on November 14-15, 2022. Management will engage in a virtual fireside chat and hold 1x1 investor meetings.
The fireside chat is scheduled for November 15 from 9:00 – 9:25 AM ET. Investors can access the chat via the provided webcast link. Larimar focuses on developing treatments for rare diseases, particularly Friedreich's ataxia, using its intracellular delivery platform.
Details
News Market Reaction – LRMR
The recorded move for LRMR in the trading session of this news was +3.64%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BALA CYNWYD, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in a virtual fireside chat and 1x1 investor meetings at the Guggenheim 4th Annual Immunology & Neurology Day, which is taking place from November 14 – 15, 2022.
Details on the fireside chat can be found below.
| Date: | Tuesday, November 15, 2022 |
| Time: | 9:00 – 9:25 AM ET |
| Webcast link: | https://guggenheim.metameetings.net/events/neuroimmunology22/sessions/43153-larimar-therapeutics-inc/webcast?gpu_only=true&kiosk=true |
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569
Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.